Peer-reviewed veterinary case report
Micropulse laser treatment for dogs with hard-to-treat glaucoma
By Sapienza, John S et al.·Published in Veterinary ophthalmology·2019·Long Island Veterinary Specialists, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Preliminary findings in 30 dogs treated with micropulse transscleral cyclophotocoagulation for refractory glaucoma.
- Species:
- dog
Plain-English summary
A group of 30 dogs with glaucoma underwent a new laser treatment called micropulse transscleral cyclophotocoagulation (MP-TSCP) to help manage their eye pressure. Before treatment, the average eye pressure was quite high at 34.5 mm Hg, but after one month, it dropped to 22 mm Hg, and continued to improve over the next few months. Most dogs experienced a reduction in the number of medications needed, and while some had complications like corneal ulcers, the overall success rate for controlling eye pressure was promising. Many dogs showed improvement, and the procedure can be repeated if necessary.
People also search for: dog glaucoma treatment · micropulse laser for dogs · high eye pressure in dogs · corneal ulcers in dogs · reducing medications for dog glaucoma
Abstract
OBJECTIVE: The purpose of this study was to report the preliminary results of a novel micropulse transscleral diode laser cyclophotocoagulation (MP-TSCP) as primary therapy for glaucomatous dogs. ANIMAL STUDIED: Client owned dogs undergoing MP-TSCP therapy at a veterinary referral center. PROCEDURE: Retrospective study of dogs with glaucoma that were treated with MP-TSCP with a minimum of 1 month (range: 1-18 months) of follow-up. Reported outcomes were intraocular pressure (IOP), treatment parameters, reduction in medications, complications, and incidence of repeat therapy. RESULTS: Thirty dogs (35 eyes) were evaluated. The mean age was 9.0 years. Mean preoperative IOP was 34.5 mm Hg. Mean postoperative IOP at 1 month (35/35 eyes) was 22 mm Hg, 2 months (26/35 eyes) was 20.5 mm Hg, 4 months (20/35 eyes) was 19 mm Hg, 6 months (10/35 eyes) was 19 mm Hg, 12 months (8/35 eyes) was 21 mm Hg. First treatment success rate was 19/35 eyes (54.3%). Repeat laser was performed in 11 eyes with 4/11 eyes responding favorably for a total IOP control of 23/35 eyes (65.7%). Mean energy levels employed were 137.5 seconds and 2351 mW at 31.3% duty cycle. Reduction in medications was from a mean of 3.6 medications preoperatively to 3.1 medications postoperatively. Complications included corneal ulcers 5/35 eyes (14.3%), uncontrolled IOP in 12/35 eyes (34.3%) and repeat treatment in 11/35 eyes (31.4%). CONCLUSIONS: MP-TSCP was successful in controlling IOP in most patients as well as to reduce postoperative medications with minimal resultant intraocular inflammation and complications. The micropulse procedure also can be repeated. Future investigations to study effective treatment parameters are warranted in a larger series of patients over a longer period of evaluation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30358935/